About us
We develop and commercialize a cell-friendly and organoid-friendly volumetric 3D bioprinter to help life scientists push the frontiers of biofabrication.
At Readily3D, we are shaping the future of biofabrication with our tomographic volumetric bioprinting technology.
Traditional bioprinters are slow, often compromise cell viability, and struggle to reproduce complex anatomical structures. Readily3D has revolutionized the field with the Tomolite: a unique bioprinter capable of creating entire cell-laden volumes in under a minute without impairing cell viability and enabling the formation of intricate features such as vascular networks.
Supporting the Tomolite is Apparite, our dedicated software platform that guides researchers through every step of the process. From file preparation and material setup to light-dose computation, object registration, and live monitoring, Apparite ensures that each print is as seamless as it is precise.
Since our launch of Tomolite v2.0, the first modular tomographic volumetric printer, researchers have gained access to powerful upgrades such as volumetric overprinting, configurable wavelengths, a registration module, and scalable print sizes. Paired with continuous improvements to Apparite, our software platform, we enable research teams worldwide to accelerate discovery, build advanced models, and push the boundaries of what's possible in biofabrication.
At Readily3D, we are committed to advancing innovation at the crossroads of 3D printing and life sciences, empowering scientists to transform ideas into living systems with unmatched speed and precision.
Company management
Paul Delrot
Co-founder and CEO
Paul co-invented the volumetric bioprinting technology at the end of his PhD studies at EPFL in 2017. After transferring what was a lab experiment into a standalone and user-friendly 3D printer, Paul co-founded Readily3D in 2020. Since then, Paul has focused on demonstrating the wide range of applications enabled by volumetric bioprinting while leading product development at Readily3D.
Randy Heyler
Strategic advisor and North America business developer
Randy Heyler has over 40 years of technical and leadership experience in the global Photonics industry, including Newport Corporation, Spectra-Physics, Coherent and Ondax, where his responsibilities included general management, technology planning, strategic and product marketing, business development, branding, and industry trade/technical association leadership. He has joined Readily3D as a strategic advisor and to lead business development in North America.
Prof. Christophe Moser
Co-founder and advisor
Christophe Moser is full professor at EPFL (Switzerland), which he joined as associate professor in 2010. A serial entrepreneur, Christophe also co-founded Ondax Inc. in 2000 (acquired by Coherent in 2018) and Composyt Light Labs in 2014 (acquired by Intel in 2014). Since 2020, he is board member of Readily3D and has an advisory role.
Prof. Riccardo Levato
Scientific advisor
Riccardo Levato is associate professor at Utrecht University and at the University Medical Center Utrecht (Netherlands). He pioneered volumetric bioprinting for tissue printing and develops biofabrication technologies for applications in tissue regeneration, organoid biology and disease modelling. As scientific advisor for Readily3D, he contributes with his long-standing expertise in bioprinting.
Supported by
Ongoing projects Eurostars VOLTA-E!3908 (December 2023 - September 2026) and Eurostars PREPPER-E!6780 (December 2024 - December 2026) supported by
You don’t find the information you need?
Let us know! Give us a call or write to us – we will be more than happy to assist you.
Request a quote
Interested in our products? Reach out to us and we will provide you with a quote.
Schedule a meeting
Feel free to contact us and we will schedule an online meeting to discuss our products.
About us
We develop and commercialize a cell-friendly and organoid-friendly volumetric 3D bioprinter to help life scientists push the frontiers of biofabrication.
At Readily3D, we are shaping the future of biofabrication with our tomographic volumetric bioprinting technology.
Traditional bioprinters are slow, often compromise cell viability, and struggle to reproduce complex anatomical structures. Readily3D has revolutionized the field with the Tomolite: a unique bioprinter capable of creating entire cell-laden volumes in under a minute without impairing cell viability and enabling the formation of intricate features such as vascular networks.
Supporting the Tomolite is Apparite, our dedicated software platform that guides researchers through every step of the process. From file preparation and material setup to light-dose computation, object registration, and live monitoring, Apparite ensures that each print is as seamless as it is precise.
Since our launch of Tomolite v2.0, the first modular tomographic volumetric printer, researchers have gained access to powerful upgrades such as volumetric overprinting, configurable wavelengths, a registration module, and scalable print sizes. Paired with continuous improvements to Apparite, our software platform, we enable research teams worldwide to accelerate discovery, build advanced models, and push the boundaries of what's possible in biofabrication.
At Readily3D, we are committed to advancing innovation at the crossroads of 3D printing and life sciences, empowering scientists to transform ideas into living systems with unmatched speed and precision.
Company management
Paul Delrot
Co-founder and CEO
Paul co-invented the volumetric bioprinting technology at the end of his PhD studies at EPFL in 2017. After transferring what was a lab experiment into a standalone and user-friendly 3D printer, Paul co-founded Readily3D in 2020. Since then, Paul has focused on demonstrating the wide range of applications enabled by volumetric bioprinting while leading product development at Readily3D.
Randy Heyler
Strategic advisor and North America business developer
Randy Heyler has over 40 years of technical and leadership experience in the global Photonics industry, including Newport Corporation, Spectra-Physics, Coherent and Ondax, where his responsibilities included general management, technology planning, strategic and product marketing, business development, branding, and industry trade/technical association leadership. He has joined Readily3D as a strategic advisor and to lead business development in North America.
Prof. Christophe Moser
Co-founder and advisor
Christophe Moser is full professor at EPFL (Switzerland), which he joined as associate professor in 2010. A serial entrepreneur, Christophe also co-founded Ondax Inc. in 2000 (acquired by Coherent in 2018) and Composyt Light Labs in 2014 (acquired by Intel in 2014). Since 2020, he is board member of Readily3D and has an advisory role.
Prof. Riccardo Levato
Scientific advisor
Riccardo Levato is associate professor at Utrecht University and at the University Medical Center Utrecht (Netherlands). He pioneered volumetric bioprinting for tissue printing and develops biofabrication technologies for applications in tissue regeneration, organoid biology and disease modelling. As scientific advisor for Readily3D, he contributes with his long-standing expertise in bioprinting.
Supported by
Ongoing projects Eurostars VOLTA-E!3908 (December 2023 - September 2026) and Eurostars PREPPER-E!6780 (December 2024 - December 2026) supported by
You don’t find the information you need?
Let us know! Give us a call or write to us – we will be more than happy to assist you.
Request a quote
Interested in our products? Reach out to us and we will provide you with a quote.
Schedule a meeting
Feel free to contact us and we will schedule an online meeting to discuss our products.
Delivery address
Readily3D SA
Route de la Corniche 4
Ground floor
CH–1066 Epalinges
CRN
CHE-261.606.782
Registered office
Readily3D SA
EPFL Innovation Park, Bât. A, CH-1015 Lausanne
Readily3D SA
EPFL Innovation Park
CH–1015 Lausanne
CRN
CHE-261.606.782
© Readily3D 2018-2025
